| Q38632012 | A perspective on sympathetic renal denervation in chronic congestive heart failure |
| Q44551633 | A prognostic index to predict long-term mortality in patients with mild to moderate chronic heart failure stabilised on angiotensin converting enzyme inhibitors |
| Q35392186 | A unifying hypothesis of body fluid volume regulation. The Lilly Lecture 1992 |
| Q43975579 | Acute heart failure: determinants of outcome |
| Q56381075 | Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology |
| Q36481392 | Approach to hyponatremia in congestive heart failure: a survey of Canadian specialist physicians and trainees |
| Q39649936 | Arrhythmias, catecholamines and electrolytes |
| Q41335271 | Baroreflex sensitivity and cardiovascular mortality in patients with mild to moderate heart failure |
| Q37339808 | Biomarkers in heart failure: a clinical review. |
| Q39554955 | Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure |
| Q78130088 | Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure |
| Q38074093 | Causes and treatment of oedema in patients with heart failure |
| Q70944841 | Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure |
| Q35374859 | Chronic heart failure in the elderly: value of cardiopulmonary exercise testing in risk stratification |
| Q69894427 | Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure |
| Q40586285 | Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure |
| Q74660324 | Clinical definition and epidemiology of advanced heart failure |
| Q36328081 | Clinical management of SIADH. |
| Q27026378 | Clinical review: practical approach to hyponatraemia and hypernatraemia in critically ill patients |
| Q37892906 | Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients. |
| Q64080183 | Clinico-etiological profile of hyponatremia among elderly age group patients in a tertiary care hospital in Sikkim |
| Q71736167 | Comparison of time domain and spectral turbulence analysis of the signal-averaged electrocardiogram for the prediction of prognosis in idiopathic dilated cardiomyopathy |
| Q39468254 | Congestive cardiac failure: advances in management |
| Q69923447 | Contributions of neuroendocrine and local autocrine-paracrine mechanisms to the pathophysiology and pharmacology of congestive heart failure |
| Q28191697 | Controversies in heart failure. Are beneficial effects of angiotensin-converting enzyme inhibitors attenuated by aspirin in patients with heart failure? |
| Q34885683 | Cost of illness of hyponatremia in the United States |
| Q28708875 | Creation of a hyponatremia registry supported by an industry-derived quality control methodology |
| Q35350198 | Current issues in advanced heart failure |
| Q34052105 | Determination of candidacy for mechanical circulatory support: importance of clinical indices |
| Q44472997 | Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality |
| Q57259671 | Differential clinical prognostic classifications in dilated and ischemic adbanced heart failure: The EPICAL study |
| Q36303947 | Digitalis and neurohormonal abnormalities in heart failure and implications for therapy |
| Q33631125 | Diuretic treatment and diuretic resistance in heart failure |
| Q79300980 | Effect of Home-Based Intervention on Hospital Readmission and Quality of Life in Middle-Aged Patients with Severe Congestive Heart Failure: A 12-Month Follow Up Study |
| Q72267719 | Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators |
| Q53159625 | Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. |
| Q39249204 | Effects of Hyponatremia Normalization on the Short-Term Mortality and Rehospitalizations in Patients with Recent Acute Decompensated Heart Failure: A Retrospective Study |
| Q40411180 | Electrolyte disturbances in chronic heart failure: metabolic and clinical aspects |
| Q42966236 | Enalapril for severe heart failure in infancy |
| Q41519180 | Epidemiology, Pathophysiology, and Management of Hyponatremic Encephalopathy |
| Q35151414 | Evaluation and management of hypo-osmolality in hospitalized patients |
| Q35772087 | Glucose and haemoglobin in the assessment of prognosis after first hospitalisation for heart failure |
| Q37612329 | Hepatic dysfunction in ambulatory patients with heart failure: application of the MELD scoring system for outcome prediction |
| Q35786320 | Heritability of serum sodium concentration: evidence for sex- and ethnic-specific effects |
| Q35656674 | Hyponatremia Predicts New-Onset Cardiovascular Events in Peritoneal Dialysis Patients |
| Q30432267 | Hyponatremia and congestive heart failure: a marker of increased mortality and a target for therapy |
| Q37810828 | Hyponatremia in Acute Decompensated Heart Failure: Mechanisms, Prognosis, and Treatment Options |
| Q37256558 | Hyponatremia in heart failure |
| Q37158850 | Hyponatremia in patients hospitalized with heart failure: a condition often overlooked in low-income settings. |
| Q86497446 | Hyponatremia in patients with heart failure |
| Q36265206 | Hyponatremia in the intensive care unit: How to avoid a Zugzwang situation? |
| Q36718655 | Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension |
| Q69807576 | Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure |
| Q38381624 | Impact of Ultrafiltration on Serum Sodium Homeostasis and its Clinical Implication in Patients With Acute Heart Failure, Congestion, and Worsening Renal Function |
| Q33611888 | Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial |
| Q33764556 | Individuality of the plasma sodium concentration |
| Q67769862 | Influence of severity of heart failure on the efficacy of angiotensin-converting enzyme inhibition |
| Q67924004 | Intractable heart failure despite angiotensin-converting enzyme inhibitors, digoxin, and diuretics: Long-term effectiveness of add-on therapy with pimobendan |
| Q52561829 | Is hyponatremia associated with mortality in pulmonary arterial hypertension? |
| Q35375388 | Is there a role for renin profiling in selecting chronic heart failure patients for ACE inhibitor treatment? |
| Q73862565 | Ischemic versus idiopathic cardiomyopathy: differing neurohumoral profiles despite comparable peak oxygen uptake |
| Q44293671 | Kidney function in heart failure |
| Q36303923 | Long-term strategies in the management of heart failure: Looking beyond ventricular function and symptoms |
| Q44418625 | Low serum sodium as a poor prognostic indicator for mortality in congestive heart failure patients |
| Q69366135 | Low-dose enalapril in severe chronic heart failure |
| Q35057482 | Molecular mechanisms of clinical concentrating and diluting disorders |
| Q34110642 | Myocardial electrical propagation in patients with idiopathic dilated cardiomyopathy |
| Q33608122 | Paradoxes of body fluid volume regulation in health and disease. A unifying hypothesis. |
| Q73251588 | Pathogenesis and management of hyponatremia |
| Q46709170 | Patterns of angiotensin-converting enzyme inhibitor prescriptions, educational interventions, and outcomes among hospitalized patients with heart failure |
| Q72666125 | Pharmacologic management of heart failure: neurohormonal agents |
| Q44050790 | Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist |
| Q44225713 | Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure |
| Q35581189 | Predicting mortality in patients with heart failure: a pragmatic approach |
| Q77353815 | Predicting short-term outcome in severely ill heart failure patients: implications regarding listing for urgent cardiac transplantation and patient selection for temporary ventricular assist device support |
| Q36806963 | Predicting survival in heart failure |
| Q40751586 | Predictors of mortality in patients with heart failure. |
| Q67746743 | Predictors of prognosis in severe chronic heart failure |
| Q41653923 | Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? |
| Q34239867 | Prognosis determination in heart failure |
| Q90674365 | Prognostic Prediction of Cardiopulmonary Exercise Test Parameters in Heart Failure Patients with Atrial Fibrillation |
| Q38730614 | Prognostic factors affecting diagnosis and treatment of congestive heart failure |
| Q35398726 | Prognostic features in patients with congestive heart failure and selection criteria for cardiac transplantation |
| Q68204869 | Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction |
| Q41867729 | Prognostic importance of the serum magnesium concentration in patients with congestive heart failure |
| Q35834936 | Prognostic value of hyponatremia in heart failure patients: an analysis of the Clinical Characteristics and Outcomes in the Relation with Serum Sodium Level in Asian Patients Hospitalized for Heart Failure (COAST) study |
| Q55314918 | Prognostic value of myocardial strain and late gadolinium enhancement on cardiovascular magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy with moderate to severely reduced ejection fraction. |
| Q99711719 | Prognostic value of serum hyponatremia for outcomes in patients with heart failure with preserved ejection fraction: An observational cohort study |
| Q34072804 | Quality of haemofiltration fluids: a potential cause of severe electrolyte imbalance. |
| Q48198136 | Reassessment of cardiovascular parameters and comorbidities in implantable cardioverter-defibrillator patients at the time of first replacement |
| Q34107621 | Region-specific changes in transient receptor potential vanilloid channel expression in the vasopressin magnocellular system in hepatic cirrhosis-induced hyponatraemia. |
| Q73370421 | Relation of daily activity levels in patients with chronic heart failure to long-term prognosis |
| Q39482471 | Renal and circulatory mechanisms in congestive heart failure |
| Q37322844 | Role of vasopressin and vasopressin receptor antagonists in type I cardiorenal syndrome |
| Q36247473 | Role of vasopressin antagonists in the management of acute decompensated heart failure |
| Q68931353 | Selection of patients for cardiac transplantation |
| Q51034448 | Serial measure of cardiac troponin T levels for prediction of clinical events in decompensated heart failure. |
| Q44202912 | Serum to urinary sodium concentration ratio is an estimate of plasma renin activity in congestive heart failure. |
| Q74820276 | Sodium |
| Q35566720 | Survival of patients with a new diagnosis of heart failure: a population based study |
| Q37806693 | Targeting Hyponatremia and Hemodynamics in Acute Decompensated Heart Failure: Is There a Role for Vasopressin Antagonists? |
| Q73031095 | The 6-min walk and peak oxygen consumption in advanced heart failure: aerobic capacity and survival |
| Q73858819 | The aspirin-angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not |
| Q57249835 | The association between serum sodium concentration, hypertension and primary cardiovascular events: a retrospective cohort study |
| Q35000605 | The central vasopressinergic system in experimental left ventricular hypertrophy and dysfunction |
| Q41436312 | The continuing evolution of mechanical ventricular assistance |
| Q36291197 | The effect of treatment on survival in congestive heart failure |
| Q70618512 | The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy |
| Q39543930 | The multifacetted role of angiotensin converting enzyme inhibitors in congestive heart failure |
| Q34532871 | The need for palliative care in the management of heart failure |
| Q35105833 | The prognostic significance of renal dysfunction in patients with chronic systolic heart failure |
| Q39511387 | The role of exercise testing in chronic heart failure |
| Q39764418 | The role of vasodilator therapy in the treatment of severe chronic heart failure |
| Q38215931 | The use of angiotensin-converting enzyme inhibitors in congestive heart failure |
| Q74635651 | Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure |
| Q36841800 | Treating hyponatremia in heart failure |
| Q37303618 | Treatment considerations for the hypertensive patient over age 55. |
| Q37262865 | Treatment options for hyponatremia in heart failure |
| Q37365495 | Upregulation of aquaporin-2 water channel expression in chronic heart failure rat |
| Q37859619 | Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet. |
| Q38215916 | Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations |
| Q36984290 | Vasopressin and aquaporin 2 in clinical disorders of water homeostasis |
| Q37258787 | Vasopressin and vasopressin antagonists in heart failure and hyponatremia |
| Q54190678 | Volumes and Na+/H+ antiporter activity of lymphocytes in patients with congestive heart failure. |
| Q34421966 | Wasting as independent risk factor for mortality in chronic heart failure |
| Q38262483 | Water disturbances in cardiac failure |
| Q64937448 | Water retention and aquaporins in heart failure, liver disease and pregnancy. |
| Q83395273 | [Hyponatremia] |